Chest
Selected Reports: ArticlesRetreatment of Recurrent Invasive Thymoma with Platinum, Doxorubicin, and Cyclophosphamide
Section snippets
Case 1
A 26-year-old Asian man was first seen at our institution in November 1978 with a diagnosis of myasthenia gravis requiring therapy with prednisone and subsequently a thymectomy in December 1978. During the next decade, he suffered recurrent upper respiratory tract infections and myasthenic exacerbations. He was readmitted to this hospital in May of 1992 for productive cough and fever. A chest radiograph done at this time showed an anterior mediastinal mass, and a subsequent CT scan confirmed
Discussion
Recently, it has become apparent that invasive thymoma is relatively sensitive to combination chemotherapy and that survival is relatively long. In two fairly large series using the PAC regimen or a combination of cisplatin, doxorubicin, vincristine, and cyclophosphamide, overall response rates ranged from 70 to 91.8%, with median durations of response averaging 11.9 months and median survival ranging from 15 to 37.7 months.3,4 Recently, PAC with etoposide and concurrent granulocyte
References (18)
- et al.
Thymoma: symposium on intrathoracic neoplasms—part IX
Mayo Clin Proc
(1993) - et al.
Recurrent ovarian carcinoma: retreatment utilizing combination chemotherapy including cisdiamminedichloroplatinum in patients previously responding to this agent
Gynecol Oncol
(1985) - et al.
Treatment of relapsed carcinoma of the ovary with cisplatinum following initial treatment with these compounds
Gynecol Oncol
(1990) - et al.
Malignancies of the thymus
- et al.
Chemotherapy for invasive thymoma: a 13-year experience
Cancer
(1991) - et al.
Cisplatin plus doxorubicin plus cyclophosphamide in metastatic or recurrent thymoma: final results of an intergroup trial
J Clin Oncol
(1994) Thymomas: current experience and future directions in therapy
Drugs
(1993)- et al.
Intensive chemotherapy with cisplatin, doxorubicin, cyclophosphamide, etoposide with granulocyte colony-stimulating factor for advanced thymoma or thymic cancer: preliminary results
Japan J Clin Oncol
(1995) - et al.
EST 2582 phase II trial of cisplatin in metastatic or recurrent thymoma
Am J Clin Oncol (CCT)
(1993)
Cited by (0)
revision accepted May 15.